Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueDepreciation ExpenseEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Akebia Therapeutics (AKBA) Receivables - Net (2016 - 2026)

Akebia Therapeutics has reported Receivables - Net over the past 10 years, most recently at $47.0 million for Q4 2025.

  • Quarterly Receivables - Net rose 36.85% to $47.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $47.0 million through Dec 2025, up 36.85% year-over-year, with the annual reading at $47.0 million for FY2025, 36.85% up from the prior year.
  • Receivables - Net was $47.0 million for Q4 2025 at Akebia Therapeutics, down from $66.2 million in the prior quarter.
  • Over five years, Receivables - Net peaked at $82.0 million in Q2 2022 and troughed at $700000.0 in Q4 2021.
  • The 5-year median for Receivables - Net is $34.7 million (2021), against an average of $39.7 million.
  • Year-over-year, Receivables - Net surged 5654.86% in 2022 and then plummeted 76.13% in 2023.
  • A 5-year view of Receivables - Net shows it stood at $700000.0 in 2021, then surged by 5654.86% to $40.3 million in 2022, then dropped by 2.47% to $39.3 million in 2023, then fell by 12.53% to $34.4 million in 2024, then skyrocketed by 36.85% to $47.0 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Receivables - Net are $47.0 million (Q4 2025), $66.2 million (Q3 2025), and $72.8 million (Q2 2025).